您现在的位置是：首页>权威专家> 肾癌

Michael Cher M.D.

Michael Cher M.D.

所在科室：外科

就职医院：Karmanos cancer center

医生擅长：

在线咨询医学顾问 电话热线：400-666-7998

医生介绍

 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Genitourinary Oncology 

·         Department/Research Program(s)

·         Urology 

·         Cancer Type(s)

·         Adrenal Cancer 
Bladder cancer 
Kidney Cancer 
Penile Cancer 
Prostate Cancer 
Testicular Cancer 
Ureter Cancer 

·         Contact Info

·         Email:
cherm@karmanos.org

 

来自 <http://www.karmanos.org/physicians/Michael-Cher?Disease=229&PageIndex=1&SortDirection=1>

 

·         Education

·         Fellowship
National Kidney Foundation Fellow, Urology Laboratory, University of Texas Southwestern Medical School, Dallas, Texas
Fellowship
Clinical and Research Fellow in Urologic oncology and Molecular Cytogenetics, University of California School of Medicine, San Francisco, California
Fellowship
Research Scholar, American Foundation for Urologic Disease, University of California School of Medicine, San Francisco, CA
Medical School
Washington University School of Medicine
Residency
General Surgery and Urology Residency: University of Texas Southwestern Medical Center, Dallas, TX

·         Professional Memberships/Associations

·         American Urological Association 
Society for Basic Urologic Research 
American Association for Cancer Research 
Southwest oncology Group 
Society of Urologic Oncology 
Society of University Urologists 

·         Board Certifications

·         American Board of Urology

·         Clinical Interests

·         Urology Surgeon 

·         Research Interests

·         Dr. Cher's research interests are focused on the biology of prostate cancer metastasis. His laboratory is actively involved in determining the biological factors responsible for prostate cancer metastasis to bone because bone is the most common location for distant spread of prostate cancer. Using various animal models, his laboratory investigates many of the biological factors involved in human prostate cancer cells interacting with the human bone microenvironment. In collaboration with other researchers at Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, more than 50 papers have been published in this area of research. Many of the findings have become the basis for clinical trials in patients. 

·         Profile

·         Michael Cher is particularly interested in minimally invasive treatments for prostate cancer, kidney cancer, and bladder cancer. For these cancers, his primary approach is robotic-assisted laparoscopic surgery using the daVinci robotic system. He uses robotic surgery for robotic radical prostatectomy, robotic radical cystectomy, and robotic partial nephrectomy. Robotic surgery provides the surgeon with tremendous visual magnification, a 3-dimensional view, and the ability to perform precise, controlled movements with the robotic surgical instruments. This offers an unparalleled opportunity to operate with precision. The end result is removal of tumors with minimal damage to surrounding tissues. Another area of Dr. Cher's expertise is image-guided treatments. only needles are used to destroy or ablate tumor tissues. For prostate cancer, real-time live imaging with ultrasound is used to place the needles, no surgical incisions are required. One approach is Cryoablation of the Prostate, wher freezing cold temperatures are used to destroy tissues. Cryoablation is appropriate for some patients with newly diagnosed prostate cancer. Cryoablation is also the preferred treatment for recurrent prostate cancer after prior radiation therapy. Another option is focal cryoablation of the prostate, wherin only a portion of the prostate is ablated. Another popular needle-based, minimally invasive image-guided approach is radioactive seed implantation to the prostate, also called brachytherapy. In concert with the Karmanos radiation therapy team, we use tiny needles to place radioactive pellets, or seeds, into the prostate. The subsequent radiation destroys the cancer.

·         Awards

·         2006 Society of Urologic oncology CapCURE Award for one of three best prostate cancer abstracts at AUA Meeting, Atlanta, GA.
Top Doc, Urology, Hour Magazine
Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year

·         Publications

·         PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. In press, Molecular Cancer. Authors: Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML and Chinni SR.
PTEN regulates PDGF ligand switch for ß-PDGFR signaling in prostate cancer. Am J Pathol. 2012 Mar;180(3):1017-27. doi: 10.1016/j.ajpath.2011.11.021. Epub 2011 Dec 28. Authors: Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR.
Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer. 2011 Nov;2(11):1009-22. doi: 10.1177/1947601912440170. Authors: Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, Dean I, Krass D, Moin K, Bonfil RD, Cher M, Sakr W, Sheng S.
Cediranib inhibits both the intraosseous growth of PDGF D-Positive prostate cancer cells and the associated bone reaction. Prostate. 2012 Sep 1;72(12):1328-38. doi: 10.1002/pros.22481. Epub 2011 Dec 27. Authors: Najy AJ, Jung YS, Won JJ, Conley-Lacomb MK, Saliganan A, Kim CJ, Heath E, Cher ML, Bonfil RD, Kim HR.
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. Oncogene. 2012 Oct 18;31(42):4527-35. doi: 10.1038/onc.2011.573. Epub 2011 Dec 12.PMID: 22158043. Authors: Huang W, Fridman Y, Bonfil RD, Ustach CV, Conley-Lacomb MK, Wiesner C, Saliganan A, Cher ML, Kim HR.

相关报道资讯

视频科普

【3月12日】肿瘤患者怎样避免人财两空？
【3月12日】肿瘤患者怎样避免人财两空？

简介：... 更多»

肿瘤临床试验患者真实采访（下）患者谈：临床试验是小白鼠吗？
肿瘤临床试验患者真实采访（下）患者谈：临床试验是小白鼠吗？

简介：... 更多»

肿瘤临床试验患者真实采访（上）临床试验带来的希望
肿瘤临床试验患者真实采访（上）临床试验带来的希望

简介：... 更多»

胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医
胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医

简介： 胃癌IV期伴有肝脏及肝胃间隙淋巴结转移，国内无标准方案，会诊得知这里胃癌5年生存率相比要高。习惯了家里的医院，还真不适应... 更多»

大肠癌伴肝转移患者赴日就医
大肠癌伴肝转移患者赴日就医

简介：大肠癌伴肝转移，本想国内治疗，但通过日ben癌研有明医院在线会诊，家人支持来院手术。非常顺利4小时完成切除和淋巴结清扫，第二... 更多»

胶质母细胞瘤和髓母细胞瘤患者赴日就医
胶质母细胞瘤和髓母细胞瘤患者赴日就医

简介： 你经历过绝望到希望吗？在国内先后被诊断为胶质母细胞瘤和髓母细胞瘤的患者。术后只做了脑部放疗，复发了。最后参加了日ben国... 更多»

肝癌患者日本国际就医案例
肝癌患者日本国际就医案例

简介： 肝癌，多年前在日ben癌研有明病院做的手术，这次来复查，结果很满意，但是还需3个月后再次复查，6月份再来，明日回国，感谢帮... 更多»

癌症患者的新方案来了！数十位国际专家带先进技术助力国内癌症患者
癌症患者的新方案来了！数十位国际专家带先进技术助力国内癌症患者

简介：癌症患者的新方案来了！数十位国际专家带先进技术助力国内癌症患者... 更多»

在线预约

绿色快速预约通道

Michael Cher M.D.

请正确填写预约人和联系人等信息，提交需求成功后，请保持联系电话畅通，客服会在48小时内与您联系确认信息。客服热线：400-666-7998

资讯 查看

愈见大"CAR"|破局复发骨髓瘤患者治疗困境,创新药物带来治疗新选择! 愈见大"CAR"|王兴兵教授团队:破局复发骨髓瘤患者治疗困境,创新药物带来治疗新选择! 4.17 全国肿瘤防治宣传周第三弹!2024抗癌新势力--TIL疗法带来生存突破 4.15 全国肿瘤防治宣传周第一弹!告诉14亿中国人如何科学防癌 2024 癌"愈"新生|第30届全国肿瘤防治宣传周大型科普云讲堂不容错过​! 15：00 愈见大"CAR"|陈丽娟教授团队:破局复发骨髓瘤患者治疗困境,创新药物带来治疗新选择! FDA批准|全癌种可用的神奇抗癌药-DS-8201,横扫数十款HER2阳性癌种,打破使用限制 "肺"常守护,"肺"常健康--2024肺癌公益科普医患交流会圆满结束

推荐专家

医院 全部医院

Michael Cher M.D.

Karmanos cancer center 外科

擅长

简介

 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Genitourinary Oncology 

·         Department/Research Program(s)

·         Urology 

·         Cancer Type(s)

·         Adrenal Cancer 
Bladder cancer 
Kidney Cancer 
Penile Cancer 
Prostate Cancer 
Testicular Cancer 
Ureter Cancer 

·         Contact Info

·         Email:
cherm@karmanos.org

 

来自 <http://www.karmanos.org/physicians/Michael-Cher?Disease=229&PageIndex=1&SortDirection=1>

 

·         Education

·         Fellowship
National Kidney Foundation Fellow, Urology Laboratory, University of Texas Southwestern Medical School, Dallas, Texas
Fellowship
Clinical and Research Fellow in Urologic oncology and Molecular Cytogenetics, University of California School of Medicine, San Francisco, California
Fellowship
Research Scholar, American Foundation for Urologic Disease, University of California School of Medicine, San Francisco, CA
Medical School
Washington University School of Medicine
Residency
General Surgery and Urology Residency: University of Texas Southwestern Medical Center, Dallas, TX

·         Professional Memberships/Associations

·         American Urological Association 
Society for Basic Urologic Research 
American Association for Cancer Research 
Southwest oncology Group 
Society of Urologic Oncology 
Society of University Urologists 

·         Board Certifications

·         American Board of Urology

·         Clinical Interests

·         Urology Surgeon 

·         Research Interests

·         Dr. Cher's research interests are focused on the biology of prostate cancer metastasis. His laboratory is actively involved in determining the biological factors responsible for prostate cancer metastasis to bone because bone is the most common location for distant spread of prostate cancer. Using various animal models, his laboratory investigates many of the biological factors involved in human prostate cancer cells interacting with the human bone microenvironment. In collaboration with other researchers at Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, more than 50 papers have been published in this area of research. Many of the findings have become the basis for clinical trials in patients. 

·         Profile

·         Michael Cher is particularly interested in minimally invasive treatments for prostate cancer, kidney cancer, and bladder cancer. For these cancers, his primary approach is robotic-assisted laparoscopic surgery using the daVinci robotic system. He uses robotic surgery for robotic radical prostatectomy, robotic radical cystectomy, and robotic partial nephrectomy. Robotic surgery provides the surgeon with tremendous visual magnification, a 3-dimensional view, and the ability to perform precise, controlled movements with the robotic surgical instruments. This offers an unparalleled opportunity to operate with precision. The end result is removal of tumors with minimal damage to surrounding tissues. Another area of Dr. Cher's expertise is image-guided treatments. only needles are used to destroy or ablate tumor tissues. For prostate cancer, real-time live imaging with ultrasound is used to place the needles, no surgical incisions are required. One approach is Cryoablation of the Prostate, wher freezing cold temperatures are used to destroy tissues. Cryoablation is appropriate for some patients with newly diagnosed prostate cancer. Cryoablation is also the preferred treatment for recurrent prostate cancer after prior radiation therapy. Another option is focal cryoablation of the prostate, wherin only a portion of the prostate is ablated. Another popular needle-based, minimally invasive image-guided approach is radioactive seed implantation to the prostate, also called brachytherapy. In concert with the Karmanos radiation therapy team, we use tiny needles to place radioactive pellets, or seeds, into the prostate. The subsequent radiation destroys the cancer.

·         Awards

·         2006 Society of Urologic oncology CapCURE Award for one of three best prostate cancer abstracts at AUA Meeting, Atlanta, GA.
Top Doc, Urology, Hour Magazine
Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year

·         Publications

·         PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. In press, Molecular Cancer. Authors: Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML and Chinni SR.
PTEN regulates PDGF ligand switch for ß-PDGFR signaling in prostate cancer. Am J Pathol. 2012 Mar;180(3):1017-27. doi: 10.1016/j.ajpath.2011.11.021. Epub 2011 Dec 28. Authors: Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR.
Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer. 2011 Nov;2(11):1009-22. doi: 10.1177/1947601912440170. Authors: Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, Dean I, Krass D, Moin K, Bonfil RD, Cher M, Sakr W, Sheng S.
Cediranib inhibits both the intraosseous growth of PDGF D-Positive prostate cancer cells and the associated bone reaction. Prostate. 2012 Sep 1;72(12):1328-38. doi: 10.1002/pros.22481. Epub 2011 Dec 27. Authors: Najy AJ, Jung YS, Won JJ, Conley-Lacomb MK, Saliganan A, Kim CJ, Heath E, Cher ML, Bonfil RD, Kim HR.
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. Oncogene. 2012 Oct 18;31(42):4527-35. doi: 10.1038/onc.2011.573. Epub 2011 Dec 12.PMID: 22158043. Authors: Huang W, Fridman Y, Bonfil RD, Ustach CV, Conley-Lacomb MK, Wiesner C, Saliganan A, Cher ML, Kim HR.

TA的文章视频

  • 在线咨询
  • 病友群
  • 联系电话
    咨询电话400-6667998
  • 返回顶部